NASDAQ$LGVN
Longeveron Inc-A · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Longeveron reported its third quarter 2024 financial results, highlighting significant progress in clinical trials and a strong financial position.
Longeveron Inc. reported a significant increase in total revenue for the first nine months of 2024, up 177% year-over-year to $1.8 million, primarily driven by contract manufacturing services and increased participant demand for the Bahamas Registry Trial. The company also reduced total operating expenses by 14% year-over-year while advancing its clinical pipeline, and expects current cash and cash equivalents to fund operations through Q4 2025.
- Phase 2b clinical trial (ELPIS II) for HLHS achieved over 80% enrollment, with FDA confirming it as pivotal for BLA submission.
- Positive data from the Phase 2a clinical trial (CLEAR MIND) for Alzheimer's disease was presented at AAIC.
- Total revenue for the first nine months of 2024 increased 177% year-over-year to $1.8 million.
- Net loss decreased by 23% to $11.9 million for the first nine months of 2024 compared to the same period in 2023.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$773K
Revenue by segment
Longeveron · $150K total across 1 segment · Q4 2023
- Clinical Trial Revenue$150K—100.0%
Forward guidance
The Company anticipates meeting with the FDA in the first quarter of 2025 to review future clinical and regulatory strategy for Alzheimer's disease. Current cash and cash equivalents are expected to be sufficient to fund Company operations through the fourth quarter of 2025. However, if the ELPIS II trial is successful and BLA enabling activities accelerate, additional financing may be needed.
Tailwinds
- Current cash and cash equivalents are expected to be sufficient to fund Company through Q4 2025.
- Anticipated meeting with FDA in Q1 2025 to review AD clinical and regulatory strategy.
- Potential BLA filing with FDA in 2026 if ELPIS II trial is successful.
- Intention to seek additional financing/capital raises/non-dilutive funding options to support accelerated activities.
- Continued investment in advancing the clinical pipeline.
Headwinds
- Clinical trial timing for rare diseases is difficult to predict, and enrollment completion for ELPIS II may occur in Q1 2025 instead of end of year.
- Accelerated operating expenses and capital expenditure requirements in 2025 due to BLA enabling activities may necessitate increased spend.
- Current cash projections may be impacted by ramped up activities and any financing transactions.
- Inability to raise additional capital necessary to continue as a going concern is a risk.
- Final marketing approval of product candidates by FDA or other regulatory authorities may be delayed, limited, or denied.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+23.1%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | — | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro